Harrow Health Acquires Japan-Approved Ophthalmic Injection For Undisclosed Sum
For an undisclosed amount, Harrow Health Inc (NASDAQ:HROW) has agreed to acquire MAQ-100 U.S. and Canadian commercial rights from Wakamoto Pharmaceutical Co Ltd. MAQ-100…
Harrow Health Acquires US And Canadian Rights To MAQ-100 From Wakamoto Pharmaceutical; Terms Not Disclosed
Harrow Health, Inc. (NASDAQ:HROW), an ophthalmic‑focused healthcare company, today announced that it has entered into an agreement with Wakamoto Pharmaceutical Co., Ltd. to acquire the U.S. and Canadian commercial rights
Harrow Health: Q2 Earnings Insights
Shares of Harrow Health (NASDAQ:HROW) were flat after the company reported Q2 results.
Quarterly Results
Earnings per share decreased 1000.00% year over year to ($0.11), which missed the estimate of ($0.03).
Harrow Health Q2 EPS $(0.11) Misses $(0.03) Estimate, Sales $18.10M Beat $15.65M Estimate
Harrow Health (NASDAQ:HROW) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.03) by 266.67 percent. This is a 1000 percent decrease over losses of $(0.01) per share from
Earnings Scheduled For August 10, 2021
Companies Reporting Before The Bell
• Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its second quarter.
NovaBay Pharmaceuticals Partners with Harrow Health’s ImprimisRx to Promote Prescription Avenova
NovaBay® Pharmaceuticals, Inc. (NYSE:NBY), a pharmaceutical company focusing on commercializing Avenova for the eye care market, announces it has partnered with ImprimisRx, one of the nation’s leading
Ladenburg Thalmann Initiates Coverage On Harrow Health with Buy Rating, Announces Price Target of $14.25
Ladenburg Thalmann analyst Jeffrey Cohen initiates coverage on Harrow Health (NASDAQ:HROW) with a Buy rating and announces Price Target of $14.25.